Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers

Trial Profile

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs ACH-0145228 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to an Achillion Pharmaceuticals media release, the company has announced that it plans to provide interim data from this trial on December 17, 2018.
    • 03 Sep 2018 Status changed from recruiting to completed.
    • 08 Aug 2018 According to an Achillion Pharmaceuticals media release, the dosing has been completed and the company expect to provide data and a strategic update in December 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top